Adjunctive homeopathic treatment in patients with severe sepsis: a randomized, double-blind, placebo-controlled trial in an intensive care unit

Background: Mortality in patients with severe sepsis remains high despite the development of several therapeutic strategies. The aim of this randomized, double-blind, placebo-controlled trial was to evaluate whether homeopathy is able to influence long-term outcome in critically ill patients suffering from severe sepsis.

Methods: Seventy patients with severe sepsis received homeopathic treatment (n=35) or placebo (n=35). Five globules in a potency of 200c were given at 12 h interval during the stay at the intensive care unit. Survival after a 30 and 180 days was recorded.

Results: Three patients (2 homeopathy, 1 placebo) were excluded from the analyses because of incomplete data. All these patients survived. Baseline characteristics including age, sex, BMI, prior conditions, APACHE II score, signs of sepsis, number of organ failures, need for mechanical ventilation, need for vasopressors or veno-venous hemofiltration, and laboratory parameters were not significantly different between groups. On day 30, there was non-statistically significantly trend of survival in favour of homeopathy (verum 81.8%, placebo 67.7%, P=0.19). On day 180, survival was statistically significantly higher with verum homeopathy (75.8% vs 50.0%, P=0.043). No adverse effects were observed.

Conclusions: Our data suggest that homeopathic treatment may be an useful additional therapeutic measure with a long-term benefit for severely septic patients admitted to the intensive care unit. A constraint to wider application of this method is the limited number of trained homeopaths.

Keywords

APACHE II - homeopathy - critically ill patients - intensive care unit - sepsis - survival - double-blind - randomized prospective - placebo-controlled study

• References

• 1 Dellinger R.P., Carlet J.M., Masur H. et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30: 536-555.
• 2 Brun-Buisson C., Doyon F., Carlet J. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995; 274: 968-974.
• 3 Reilly D.T., Taylor M.A., Beattie N.G.M. et al. Is evidence for homoeopathy reproducible?. The Lancet 1994; 344: 1601-1606.
• 4 Linde K., Clausius N., Ramirez G. et al. Are the clinical effects of homoeopathy placebo effects? A meta-analysis of placebo-controlled trials. The Lancet 1997; 350: 834-843.
• 5 Jacobs J., Jiménez L.M., Gloyd S.S. et al. Treatment of acute childhood diarrhea with homeopathic medicine: a randomized clinical trial in Nicaragua. Pediatrics 1994; 93: 719-725.
• 6 Samal S., Geckeler K.E. Unexpected solute aggregation in water on dilution. Chem Commun 2001: 2224-2225
• 7 Rey L. Thermoluminescence of ultra-high dilutions of lithium chloride and sodium chloride. Physica A 2003; 323: 67-74.
• 8 Frass M. Homöopathie—Ihr Stellenwert auf einer Intensivstation. In “Durch Ähnliches Heilen—Homöopathie in Österreich”, (Homeopathy—its value in intensive care medicine. In “Like cures like—Homeopathy in Austria) second edition, pp 139–147, 2005. Ed.: Peter König, Orac Verlag, Austria. ISBN 3-7007-2998-7.
• 9 Bone R.C., Fisher C.J., Clemmer T.P. et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658.
• 10 Knaus W.A., Draper E.A., Wagner D.P. et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
• 11 Dellinger R.P. Cardiovascular management of septic shock. Crit Care Med 2003; 31: 946-955.
• 12 Friedman G., Silva E., Vincent J.L. Has the mortality of septic shock changed with time?. Crit Care Med 1998; 26: 2078-2086.
• 13 Rivers E., Nguyen B., Havstad S. et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377.
• 14 Weinstein M.P., Reller L.P., Murphy J.R. et al. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis 1983; 5: 35-53.
• 15 Annane D., Sebille V., Charpentier C. et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-871.
• 16 Briegel J., Forst H., Haller M. et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27: 723-732.
• 17 Bollaert P.E., Charpentier C., Levy B. et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645-650.
• 18 Bernard G.R., Vincent J.L., Laterre P.F. et al. Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
• 19 Amato M.B., Barbas C.S., Medeiros D.M. et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338: 347-354.
• 20 Stewart T.E., Meade M.O., Cook D.J. et al. Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome Pressure- and Volume-Limited Ventilation Strategy Group. N Engl J Med 1998; 338: 355-361.
• 21 Brochard L., Roudat-Thoraval F. et al. Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trial Group on Tidal Volume reduction in ARDS. Am J Respir Crit Care Med 1998; 158: 1831-1838.
• 22 Brower R.G., Shanholtz C.B., Fessler H.E. et al. Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. Crit Care Med 1999; 27: 1492-1498.
• 23 Esteban A., Alia I., Tobin M.J. et al. Effect of spontaneous breathing trial duration on outcome of attempts to discontinue mechanical ventilation. Spanish Lung Failure Collaborative Group. Am J Respir Crit Care Med 1999; 159: 512-518.
• 24 Ely E.W., Baker A.M., Dunagan D.P. et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. N Engl J Med 1996; 335: 1864-1869.
• 25 Esteban A., Alia I., Gordo F. et al. Extubation outcome after spontaneous breathing trials with T-tube or pressure support ventilation. The Spanish Lung Failure Collaborative Group. Am J Respir Crit Care Med 1997; 156: 459-465.
• 26 Kollef M.H., Levy N.T., Ahrens T.S. et al. The use of continuous IV sedation is associated with prolongation of mechanical ventilation. Chest 1998; 114: 541-548.
• 27 Kress J.P., Pohlman A.S., O’Connor M.F. et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342: 1471-1477.
• 28 Berghe G van den. Wouters P., Weekers F. et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367.